DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tepotinib
Tepotinib
Treatment and Testing Guidelines
Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
Crusader Q2 2020 Research Edition Download
Tepotinib) Tablets, for Oral Use Any Severity
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
Original Article the Selective C-Met Inhibitor Tepotinib Can Overcome
Issue 18, July 2020 Newsletter
Entrectinib in Patients with Advanced Or Metastatic NTRK Fusion-Positive
Presentación De Powerpoint
(FDA) Approved Bristol Myers Squibb's (Bms.Com) Br
Tepotinib (Tepmetko) EOCCO POLICY
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
BRAF, MET, and Her2 Mutations in Lung Cancer
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Impressive Response to Dabrafenib, Trametinib, and Osimertinib in a Metastatic EGFR-Mutant/BRAF V600E Lung Adenocarcinoma Patien
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors And
Top View
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing Gsk3β, E-Cadherin, and Mucin 5AC and 6 Levels
Phase 1B/2 Trial of Tepotinib in Sorafenib Pretreated Advanced Hepatocellular Carcinoma with MET Overexpression
Non-Small Cell Lung Cancer
Drugs with Special Ordering Procedures (SAP Chart)
Therapy for Stage IV Non–Small-Cell Lung Cancer with Driver Alterations: ASCO and OH (CCO) Guideline Update
Download This Activity, Go to Reachmd.Com/CME
Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
2018 ASCO Annual Meeting J Clin Oncol 36, 2018 (Suppl; Abstr
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Point of Care Molecular Testing Streamlining Cancer Care from the Anatomic Pathologist’S Office
The Race to Target MET Exon 14 Skipping Alterations in Non-Small Cell
Phase II Two-Arm Study of Tepotinib + Osimertinib in Patients with EGFR-Mutant NSCLC and Acquired
First-In-Man Phase I Trial of the Selective MET Inhibitor Tepotinib In
Draft Scope Pre Referral PDF 286.18 KB
Optimizing Use of Biomarkers in Managing Metastatic Non−Small Cell Lung Cancer the Role of the Oncology Health Care Team Faculty Information
Targeting Driver Mutations in Non-Small-Cell Lung Cancer, Beyond the Usual Suspects (EGFR and ALK)
Final Scope PDF 270 KB
614.Full.Pdf
409 Oncology Drugs
Publication Agenda CHMP 07-10 December 2020
January 28-31, 2021 | Worldwide Virtual Event Connect with Us
Prior Authorization Criteria
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant NSCLC
Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines
Tyrosine Kinase Receptors in Oncology